Pazopanib · Votrient
Small molecule
Evidence outlook
Approved: Renal Cell Carcinoma, Soft Tissue Sarcoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (2)
- Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes.
- Metastatic Renal Cell Carcinoma VOTRIENT (pazopanib hydrochloride) is indicated for the treatment of patients with metastatic renal cell (clear cell) carcinoma (mRCC) as first-line systemic therapy or as second-line systemic therapy after treatment with cytokines for metastatic disease. Approval of VOTRIENT in mRCC is based on significant progression-free survival benefit in patients with mRCC of good performance status (ECOG 0-1). Prolongation of overall survival was not demonstrated nor were quality-of-life differences shown between patients receiving VOTRIENT versus placebo in the...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00334282 NCT00334282 · Renal Cell Carcinoma Run by former owner GlaxoSmithKline This was a randomized, quadruple-blind, placebo-controlled trial involving 435 participants, with progression-free survival assessed by an independent imaging committee as the primary clinical endpoint. The primary comparison favored pazopanib and was statistically significant (hazard ratio 0.46, 95% CI 0.34–0.62; p=0.0000001), supporting strong evidence from this trial. Registry: NCT00334282 | 3 | Progression-free Survival (Randomization until progression (up to 2 years)) 2008-05 | Progression-free Survival (Randomization until progression (up to 2 years)): Pazopanib 800 mg 9.2 months (95% CI 7.4 to 12.9) | Placebo 4.2 months (95% CI 2.8 to 5.6) | Reliable signal | link ↗ |
View 3 more trials
COMPARZ NCT00720941 · Renal Cell Carcinoma The study was a large randomized comparison of pazopanib with active-control sunitinib, with 557 and 553 participants respectively, and used progression-free survival as its primary clinical endpoint. Pazopanib met the prespecified non-inferiority criterion, but the open-label design provides less protection against bias than a blinded trial. Registry: NCT00720941 | 3 | Progression-free Survival (PFS) (From randomization until the earliest date of disease progression or date of death from any cause, assessed up to approximately 39 months) 2012-05-21 | Progression-free Survival (PFS) (From randomization until the earliest date of disease progression or date of death from any cause, assessed up to approximately 39 months): Pazopanib 800 mg 8.4 Months (95% CI 8.3 to 10.9) | Sunitinib 50 mg 9.5 Months (95% CI 8.3 to 11.1) | Partial signal | link ↗ |
PROTECT NCT01235962 · Renal Cell Carcinoma PROTECT was a randomized, double-blind, placebo-controlled Phase 3 trial of adjuvant pazopanib after nephrectomy in localized or locally advanced renal cell carcinoma, with 1,538 patients enrolled. Its single primary endpoint was disease-free survival with the 600 mg initial dose against placebo (571 vs 564 patients). The adjusted hazard ratio was 0.862 (95% CI 0.699 to 1.063, p=0.1649), which is not statistically significant, so the primary endpoint was missed. The figures come from the ClinicalTrials.gov posted results. Registry: NCT01235962 | 3 | Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo (approximately 5 years) 2015-10-15 | Disease-free survival, pazopanib 600 mg initial dose (n=571) vs placebo (n=564), ITT 600 population: adjusted HR 0.862 (95% CI 0.699 to 1.063); stratified log-rank p=0.1649. Median DFS not reached in either arm. | not yet graded | link ↗ |
NCT00387764 NCT00387764 · Carcinoma, Renal Cell Run by former owner GlaxoSmithKline This open-label, single-arm extension of the VEG105192 trial gave pazopanib 800 mg daily to 80 patients with advanced renal cell carcinoma whose disease had progressed on placebo in that earlier study. There was no randomization, blinding or control arm, and every primary endpoint measured safety and tolerability. Adverse events occurred in 78 of 80 participants and serious adverse events in 27; no efficacy comparison was made. Registry: NCT00387764 | 3 | Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) (From Baseline to Follow-up (up to 6.230 years)); Number of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Severity, Per National Cancer Institute (NCI) Common Terminology Criteria in Adverse Events (CTCAE) (From Baseline to Follow-up (up to 6.230 years)); Number of Participants With Adverse Events Related to Investigational Product (From Baseline to Follow-up (up to 6.230 years)); Median Time on Investigational Product (From Baseline to investigational product discontinuation (up to 6.230 years)); Number of Participants With the Indicated Worst-case Toxicity Grade Increase From Baseline for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline (From Baseline to investigational product discontinuation (up to 6.230 years)); Number of Participants With the Indicated Worst-case Grade Increase From Baseline for the Indicated Hematology Parameters at Any Time Post-Baseline (From Baseline to investigational product discontinuation (up to 6.230 years)); Number of Participants With the Indicated Shift From Baseline in Blood Pressure at Any Time Post-Baseline (From Baseline to investigational product discontinuation (up to 6.230 years)); Number of Participants With the Indicated Shift in Heart Rate From Baseline at Any Time Post-Baseline (From Baseline to investigational product discontinuation (up to 6.230 years)); Number of Participants With a Change From Baseline to the Indicated Worst-case Post-Baseline Bazett's Heart Rate-corrected QT Interval (QTc) Value (From Baseline to investigational product discontinuation (up to 6.230 years)) 2009-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (128)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (68)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (10)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Appears in other studies (8)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other Multi-kinase inhibitor (VEGFR/PDGFR/KIT) drugs
Regorafenib. Compare all 2 Multi-kinase inhibitor (VEGFR/PDGFR/KIT) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Renal Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pazopanib (Votrient): this drug | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | Featured results are non-efficacy only in this race | |
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Avelumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Axitinib | Approved | Small molecule | VEGFR1/2/3 | Partial signal | NCT02684006: Primaries in PD-L1-positive patients, avelumab + axitinib vs sunitinib: PFS (BICR) median 13.8 vs 7.2 months, hazard ratio 0.61 (95% CI 0.475 to 0.790), p=0.0001, met; OS median 43.2 vs 36.2 months, hazard ratio 0.86 (95% CI 0.701 to 1.057), p=0.1509, not significant (CT.gov posted results). | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Belzutifan (Welireg) | Approved | Small molecule | HIF-2alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | No reviewed efficacy summary in this indication | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT01668784: Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02811861: Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11) NCT04704219: Objective Response Rate (ORR) (Up to approximately 47 months): Pembrolizumab + Lenvatinib 50.6 Percentage of participants (95% CI 42.6 to 58.7) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Regorafenib | Approved(overall) | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Phase 3 | Small molecule | VEGFR1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| Savolitinib (Orpathys) | Phase 3 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ciforadenant | Phase 1/2 | Small molecule | adenosine A2A | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Votrient (Pazopanib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.